Comparing the effect of magnesium sulfate nebulizer and ipratropium bromide nebulizer in children with asthma

Comparison of the effectiveness of magnesium sulfate nebulizer and ipratropium bromide in children with asthma attacks admitted to Masih Deneshvari Hospital in Tehran in 1402

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230403057810N1

Enrollment

Registered

2023-04-08

Start date

2023-05-05

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Magnesium sulfate nebulizer in asthma attack. Severe persistent asthma with (acute) exacerbation

Interventions

Intervention 1: ?First intervention group: Magnesium sulfate nebulizer (magnesium sulfate 50%, 0.3 mL (150 mg) diluted with 2.2 mL of distilled water). Intervention 2: Second intervention group: Iprat

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Children with asthma attack Over 2 years to 18 years After receiving primary asthma attack treatment (salbutamol) Stable clinical conditions

Exclusion criteria

Exclusion criteria: Immunodeficiency Underlying disease

Design outcomes

Primary

Measure	Time frame
Respiratory rate. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Lung examination.;Heart rate. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Cardiac examination.;Blood oxygen saturation percentage. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Pulse oximetry device.;Wheezing. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Lung examination with a stethoscope.;Duration of symptoms (less than or more than 6 hours). Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Physical examination.;Treatments after nebulizer administration. Timepoint: After repeated examinations. Method of measurement: General condition of the patient.	—

Measure

Time frame

Respiratory rate. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Lung examination.;Heart rate. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Cardiac examination.;Blood oxygen saturation percentage. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Pulse oximetry device.;Wheezing. Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Lung examination with a stethoscope.;Duration of symptoms (less than or more than 6 hours). Timepoint: Intervals before administration and 30, 60 and 120 minutes after receiving the drug. Method of measurement: Physical examination.;Treatments after nebulizer administration. Timepoint: After repeated examinations. Method of measurement: General condition of the patient.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNiloofar Esfahanian

Shahid Beheshti University of Medical Sciences

n.esfahanian@gmail.com+98 21 2269 0913

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026